Treatment outcomes for older women with advanced ovarian cancer: Results from a phase III clinical trial (GOG182).

5030 Background: GOG182 proved that the incorporation of a third cytotoxic agent to carboplatin and paclitaxel (C+P) did not improve overall survival (OS) or progression-free survival (PFS) for patients (pts) with advanced-stage epithelial ovarian carcinoma (EOC) after a cytoreduction surgery (Bookman, JCO, 2009). We will characterize the outcome and toxicity differences seen in pts 70 yrs and older enrolled on this phase III trial. Methods: Pts with stages III/IV disease were stratified by coordinating center, residual tumor and intent for interval cytoreduction. Pts were randomly assigned among 5 arms that incorporated gemcitabine, liposomal doxorubicin or topotecan compared with C+P. The primary end point was OS, determined by pairwise comparison to C+P arm. Pts’ characteristics, treatment compliance, toxicities and clinical outcomes were compared between the pts ≥ 70 yrs and < 70 yrs. Results: Of 3,686 eligible pts, median age was 59 yrs and 620 pts (16.8%) were ≥ 70 yrs. Older pts were distributed eq...